قالب وردپرس درنا توس
Home / Health / Epileptologist Explains New FDA Approved Cannabis Drug

Epileptologist Explains New FDA Approved Cannabis Drug



TYLER, TX (KLTV) –

The medical field is making progress for people with epilepsy. In February, patients with refractory epilepsy in Texas were given access to cannabidiol or CBD oil. Starting on Monday, some epilepsy patients across the country will receive Epidiolex.

"It has been approved to treat patients with two very specific forms of epilepsy, Lennox-Gastaut syndrome and Dravet's syndrome." Epileptolog. Gina of Northeast Texas Said Jetter. "And usually these are children who are very hard on epilepsy."

The two syndromes can affect children as young as two or three years old. Patients usually have different types of seizures such as seizures and atonic seizures.

"Typically, patients with Lennox-Gastaut and Dravet's syndrome may have tens to hundreds of seizures per day," Jetter said.

This is the first drug approved by the FDA for the treatment of Dravet's Syndrome, which affects nearly 1

2,000 patients in the US

In a statement, the FDA said, "This is an important medical advance It is also important to note that this is not an approval of marijuana or any of its components. "

Dr. Jetter believes that this approval could lead to further research into medical marijuana.

"We really need good studies that show that this drug works not only in epilepsy," Jetter said. "But in other neurological diseases and other diseases in general."

Epidiolex is expected to be available later this fall, but Jetter says she is looking forward to working with her patients and this new medication.

"We need more drugs now to help people," Jetter said. "Because we have many people who are suffering and in pain, and we need to be able to help them, and when we classify and study it, it gets really good."

Dr. Jetter says that unlike the medicines offered to patients in Texas, Epidiolex will be covered by insurance because it is approved at the federal level.

Copyright 2018 KLTV. All rights reserved.


Source link